47 completed. 47 Phase 2, 15 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 47 | Completed 47 |
| Phase 1 | 15 | Completed 15 |
Follow Refractory Chronic Lymphocytic Leukemia: new trials by email Literature Review of Refractory Chronic Lymphocytic Leukemia trials Research Report on Refractory Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Ibrutinib, Venetoclax - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Completed | Steven E. Coutre | 22 | 2017-09-26 | 2021-09-29 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Ibrutinib, Laboratory Biomarker Analysis - Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 23 | 2016-11-01 | 2023-10-23 |
| Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation Ibrutinib, Laboratory Biomarker Analysis, Nivolumab - Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 37 | 2015-06-19 | 2024-03-20 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
| Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL MOR00208, lenalidomide, Correlative Studies - Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 41 | 2014-01-17 | 2025-12-15 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes - CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 204 | 2013-05-22 | 2022-05-25 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant allogeneic cytomegalovirus-specific cytotoxic T lymphocytes - Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 1 | 2012-04-01 | 2017-02-15 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Dinaciclib, Laboratory Biomarker Analysis, Ofatumumab - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2012-01-01 | 2018-03-15 |
| Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia Dasatinib, Laboratory Biomarker Analysis, Pharmacological Study - Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia | Phase 2 | Completed | OHSU Knight Cancer Institute | 19 | 2011-10-01 | 2021-04-08 |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Akt Inhibitor MK2206, Bendamustine Hydrochloride, Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2011-09-01 | 2017-09-15 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2011-01-01 | 2020-06-23 |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 77 | 2010-12-01 | 2019-12-09 |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation - B-Cell Prolymphocytic Leukemia, Hypodiploidy | Phase 2 | Completed | Fred Hutchinson Cancer Center | 16 | 2010-03-18 | 2019-06-11 |
Showing 20 of 47. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (47) · Lymphoma, Mantle-Cell (26) · Lymphoma, Follicular (24) · Lymphoma, Large B-Cell, Diffuse (23) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (23) · Hodgkin Disease (22) · Lymphoma, B-Cell, Marginal Zone (22) · Lymphoma, Non-Hodgkin (22) · Waldenstrom Macroglobulinemia (21) · Burkitt Lymphoma (17) · Lymphoma, Large-Cell, Immunoblastic (17) · Multiple Myeloma (17) · Leukemia, Myeloid, Acute (16) · Leukemia, Hairy Cell (13) · Lymphoma, T-Cell, Cutaneous (13)
Chronic Disease (47) · Disease Attributes (47) · Hematologic Diseases (47) · Hemic and Lymphatic Diseases (47) · Immune System Diseases (47) · Immunoproliferative Disorders (47) · Leukemia (47) · Leukemia, B-Cell (47) · Leukemia, Lymphoid (47) · Lymphatic Diseases (47) · Lymphoproliferative Disorders (47) · Neoplasms by Histologic Type (47) · Pathologic Processes (47) · Pathological Conditions, Signs and Symptoms (47) · Neoplasms (46)
Mycophenolic Acid (17) · Whole-Body Irradiation (16) · fludarabine phosphate (16) · Peripheral Blood Stem Cell Transplantation (13) · Cyclosporine (12) · Tacrolimus (8) · Cyclophosphamide (7) · Cyclosporins (7) · Rituximab (6) · ibrutinib (4) · Alemtuzumab (3) · In Situ Hybridization, Fluorescence (3) · Melphalan (3) · Methotrexate (3) · Sirolimus (3)
Fred Hutchinson Cancer Center (20) · National Cancer Institute (NCI) (12) · Mayo Clinic (4) · Alexey Danilov, MD (1) · Case Comprehensive Cancer Center (1) · Chinese PLA General Hospital (1) · M.D. Anderson Cancer Center (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Steven E. Coutre (1) · University of Chicago (1) · University of Washington (1) · Vanderbilt-Ingram Cancer Center (1)
United States (46) · Italy (8) · Germany (4) · Denmark (3) · China (1)
Brenda Sandmaier (7) · David Maloney (5) · John Byrd (3) · Mohamed Sorror (2) · Neil Kay (2) · Tait Shanafelt (2) · Wei Ding (2) · Bhagirathbhai Dholaria, M.D. (1) · Brenda Cooper, MD (1) · Cameron Turtle (1) · Craig Okada, M.D. (1) · Craig Reeder (1) · George Chen (1) · Hongtao Liu (1) · Jennifer Woyach, MD (1)
PMID 32499241, PMID 34515338, PMID 19826119, PMID 19900571, PMID 20837940, PMID 21072184, PMID 22289993, PMID 24990615, PMID 25085357, PMID 27111235, PMID 28314788, PMID 28424162, PMID 29038338, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31481800, PMID 31648294, PMID 32603426, PMID 32967009, PMID 34196037, PMID 34666344, PMID 36287248, PMID 37774014, PMID 39333103, PMID 41804087, PMID 42389828
P30CA015704 (16), P01CA018029 (7), P01CA078902 (4), U10CA025224 (4), P30CA015083 (3), N01CM62207 (2), P30CA016058 (2), R01CA136551 (2), U01CA076576 (2), N01CM00070 (1), N01CM62201 (1), N01CM62202 (1), N01CM62205 (1), P30CA008748 (1), P30CA014599 (1)